Aradigm Corporation (NASDAQ:ARDM) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokers have set a 12-month consensus price objective of $10.00 for the company, according to Zacks. Zacks has also given Aradigm an industry rank of 107 out of 265 based on the ratings given to related companies.
A number of research analysts have issued reports on ARDM shares. Zacks Investment Research raised shares of Aradigm from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research report on Tuesday, September 5th. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $10.00 price objective (up from $7.50) on shares of Aradigm in a research report on Monday, September 25th.
Shares of Aradigm (ARDM) traded down $0.45 during midday trading on Friday, hitting $5.37. 203,462 shares of the company traded hands, compared to its average volume of 160,720. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of -1.59. Aradigm has a 12 month low of $0.78 and a 12 month high of $5.94.
Aradigm (NASDAQ:ARDM) last issued its earnings results on Thursday, November 2nd. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.05. The company had revenue of $2.73 million for the quarter. Aradigm had a negative net margin of 118.37% and a negative return on equity of 665.03%. analysts anticipate that Aradigm will post -0.74 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Zacks: Aradigm Corporation (ARDM) Given $10.00 Average Price Target by Brokerages” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/12/15/zacks-aradigm-corporation-ardm-given-10-00-average-price-target-by-brokerages.html.
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm and related companies with MarketBeat.com's FREE daily email newsletter.